Pleural catheters after thoracoscopic treatment of malignant pleural effusion: a randomized comparative study on quality of life

Research output: Contribution to journalArticle

Abstract

Background: Malignant pleural effusion (MPE) complicates many neoplasms and its incidence is expected to rise in parallel with the aging population and longer survival of cancer patients. Although a clear consensus exists on indwelling catheters in patients with poor performance status, no study has hitherto compared different devices in patients requiring temporary or definitive drainage following talc poudrage.

Methods: This is a prospective, two-arm, pilot study on patients with MPE undergoing talc poudrage, comparing two different catheters (PleurX® versus Pleurocath®) positioned because of the inefficacy of the procedure or the high risk of short-term failure. End points of the study were quality of life (QoL), median dyspnea and chest pain assessment by EORTC questionnaires and a 100 mm visual analog scale, total in-hospital length of stay and frequency of serious adverse events.

Results: No difference was observed between the two groups in in mean dyspnea and mean chest pain in any questions of the EORTC QLQ-C30 and QLQ-LC13 questionnaires. Duration of the procedure was significantly longer in the PleurX® group versus the Pleurocath® group (72±33 versus 44±13 minutes; P=0.03). No difference was observed between the two groups in total length of hospital stay (P=1.00) or complication rate (P=1.00).

Conclusions: For the cohort of patients still needing indwelling pleural catheters (PC) after thoracoscopic talc poudrage, PleurX® is suggested when drain removal is unlikely due to short life expectancy or the high chance of pleurodesis failure. Conversely, Pleurocath® should be recommended in all other patients as it is faster to place and easier to remove.

Keywords: Malignant pleural effusion (MPE); talc poudrage; indwelling pleural catheter (indwelling PC).

Original languageEnglish
Pages (from-to)2999-3004
Number of pages6
JournalJournal of Thoracic Disease
Volume10
Issue number5
DOIs
Publication statusPublished - May 2018

Fingerprint

Malignant Pleural Effusion
Talc
Catheters
Quality of Life
Indwelling Catheters
Length of Stay
Chest Pain
Dyspnea
Therapeutics
Pleurodesis
Pain Measurement
Life Expectancy
Visual Analog Scale
Drainage
Neoplasms
Equipment and Supplies
Survival
Incidence
Population

Cite this

@article{5589570eed2b43a9aef14c598932cbfc,
title = "Pleural catheters after thoracoscopic treatment of malignant pleural effusion: a randomized comparative study on quality of life",
abstract = "Background: Malignant pleural effusion (MPE) complicates many neoplasms and its incidence is expected to rise in parallel with the aging population and longer survival of cancer patients. Although a clear consensus exists on indwelling catheters in patients with poor performance status, no study has hitherto compared different devices in patients requiring temporary or definitive drainage following talc poudrage.Methods: This is a prospective, two-arm, pilot study on patients with MPE undergoing talc poudrage, comparing two different catheters (PleurX{\circledR} versus Pleurocath{\circledR}) positioned because of the inefficacy of the procedure or the high risk of short-term failure. End points of the study were quality of life (QoL), median dyspnea and chest pain assessment by EORTC questionnaires and a 100 mm visual analog scale, total in-hospital length of stay and frequency of serious adverse events.Results: No difference was observed between the two groups in in mean dyspnea and mean chest pain in any questions of the EORTC QLQ-C30 and QLQ-LC13 questionnaires. Duration of the procedure was significantly longer in the PleurX{\circledR} group versus the Pleurocath{\circledR} group (72±33 versus 44±13 minutes; P=0.03). No difference was observed between the two groups in total length of hospital stay (P=1.00) or complication rate (P=1.00).Conclusions: For the cohort of patients still needing indwelling pleural catheters (PC) after thoracoscopic talc poudrage, PleurX{\circledR} is suggested when drain removal is unlikely due to short life expectancy or the high chance of pleurodesis failure. Conversely, Pleurocath{\circledR} should be recommended in all other patients as it is faster to place and easier to remove.Keywords: Malignant pleural effusion (MPE); talc poudrage; indwelling pleural catheter (indwelling PC).",
author = "Francesco Petrella and Patrick Maisonneuve and Alessandro Borri and Monica Casiraghi and Stefano Donghi and Sava Durkovic and Niccolo Filippi and Domenico Galetta and Roberto Gasparri and Juliana Guarize and {Lo Iacono}, Giorgio and Mariolo, {Alessio Vincenzo} and Adele Tessitore and Lorenzo Spaggiari",
year = "2018",
month = "5",
doi = "10.21037/jtd.2018.05.49",
language = "English",
volume = "10",
pages = "2999--3004",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "AME Publishing Company",
number = "5",

}

TY - JOUR

T1 - Pleural catheters after thoracoscopic treatment of malignant pleural effusion

T2 - a randomized comparative study on quality of life

AU - Petrella, Francesco

AU - Maisonneuve, Patrick

AU - Borri, Alessandro

AU - Casiraghi, Monica

AU - Donghi, Stefano

AU - Durkovic, Sava

AU - Filippi, Niccolo

AU - Galetta, Domenico

AU - Gasparri, Roberto

AU - Guarize, Juliana

AU - Lo Iacono, Giorgio

AU - Mariolo, Alessio Vincenzo

AU - Tessitore, Adele

AU - Spaggiari, Lorenzo

PY - 2018/5

Y1 - 2018/5

N2 - Background: Malignant pleural effusion (MPE) complicates many neoplasms and its incidence is expected to rise in parallel with the aging population and longer survival of cancer patients. Although a clear consensus exists on indwelling catheters in patients with poor performance status, no study has hitherto compared different devices in patients requiring temporary or definitive drainage following talc poudrage.Methods: This is a prospective, two-arm, pilot study on patients with MPE undergoing talc poudrage, comparing two different catheters (PleurX® versus Pleurocath®) positioned because of the inefficacy of the procedure or the high risk of short-term failure. End points of the study were quality of life (QoL), median dyspnea and chest pain assessment by EORTC questionnaires and a 100 mm visual analog scale, total in-hospital length of stay and frequency of serious adverse events.Results: No difference was observed between the two groups in in mean dyspnea and mean chest pain in any questions of the EORTC QLQ-C30 and QLQ-LC13 questionnaires. Duration of the procedure was significantly longer in the PleurX® group versus the Pleurocath® group (72±33 versus 44±13 minutes; P=0.03). No difference was observed between the two groups in total length of hospital stay (P=1.00) or complication rate (P=1.00).Conclusions: For the cohort of patients still needing indwelling pleural catheters (PC) after thoracoscopic talc poudrage, PleurX® is suggested when drain removal is unlikely due to short life expectancy or the high chance of pleurodesis failure. Conversely, Pleurocath® should be recommended in all other patients as it is faster to place and easier to remove.Keywords: Malignant pleural effusion (MPE); talc poudrage; indwelling pleural catheter (indwelling PC).

AB - Background: Malignant pleural effusion (MPE) complicates many neoplasms and its incidence is expected to rise in parallel with the aging population and longer survival of cancer patients. Although a clear consensus exists on indwelling catheters in patients with poor performance status, no study has hitherto compared different devices in patients requiring temporary or definitive drainage following talc poudrage.Methods: This is a prospective, two-arm, pilot study on patients with MPE undergoing talc poudrage, comparing two different catheters (PleurX® versus Pleurocath®) positioned because of the inefficacy of the procedure or the high risk of short-term failure. End points of the study were quality of life (QoL), median dyspnea and chest pain assessment by EORTC questionnaires and a 100 mm visual analog scale, total in-hospital length of stay and frequency of serious adverse events.Results: No difference was observed between the two groups in in mean dyspnea and mean chest pain in any questions of the EORTC QLQ-C30 and QLQ-LC13 questionnaires. Duration of the procedure was significantly longer in the PleurX® group versus the Pleurocath® group (72±33 versus 44±13 minutes; P=0.03). No difference was observed between the two groups in total length of hospital stay (P=1.00) or complication rate (P=1.00).Conclusions: For the cohort of patients still needing indwelling pleural catheters (PC) after thoracoscopic talc poudrage, PleurX® is suggested when drain removal is unlikely due to short life expectancy or the high chance of pleurodesis failure. Conversely, Pleurocath® should be recommended in all other patients as it is faster to place and easier to remove.Keywords: Malignant pleural effusion (MPE); talc poudrage; indwelling pleural catheter (indwelling PC).

U2 - 10.21037/jtd.2018.05.49

DO - 10.21037/jtd.2018.05.49

M3 - Article

C2 - 29997967

VL - 10

SP - 2999

EP - 3004

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - 5

ER -